Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can we cure indolent lymphomas?

F Cabanillas1

  • 1Department of Hematology, Lymphoma Section, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curability Potential of Low-Grade Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2007
Same author

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Indolent lymphomas may be curable, challenging the notion they are incurable. Molecular remission, detected by PCR, correlates with long-term survival and aids in developing new treatments.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Indolent lymphomas are widely considered incurable.
  • However, evidence suggests potential curability in certain stages and subsets.
  • Molecular remission is a key indicator of treatment success.

Purpose of the Study:

  • To explore the potential curability of indolent lymphomas.
  • To evaluate the role of Polymerase Chain Reaction (PCR) in assessing remission and predicting outcomes.
  • To investigate the impact of Interferon (IFN) and specific genetic markers on treatment efficacy.

Main Methods:

  • Analysis of literature data on indolent lymphoma patient outcomes.
  • Serial monitoring of molecular complete remission using PCR in blood or marrow samples.

Related Experiment Videos

  • Evaluation of treatment regimens including Interferon (IFN) and alternating triple therapy.
  • Assessment of the clinical significance of bcl-2 breakpoint site variations.

    • Main Results:

    • Patients with early-stage (Ann Arbor I-II) indolent lymphomas show potential for cure.
    • Persistently negative PCR states correlate with infrequent relapse, while positive states indicate higher relapse rates.
    • Interferon (IFN) has demonstrated a 2-fold increase in remission duration for advanced indolent lymphomas, associated with improved survival.
    • Specific bcl-2 breakpoint sites may indicate a more aggressive, potentially curable lymphoma subset.

    Conclusions:

    • Indolent lymphomas, particularly in early stages or specific genetic subsets, may be curable.
    • Polymerase Chain Reaction (PCR) serves as a valuable surrogate end point for clinical trials, expediting new treatment development.
    • Interferon (IFN) and intensive combination therapies can improve remission quality and duration, impacting survival.
    • Further research is needed to confirm the curability of aggressive subsets identified by bcl-2 breakpoint analysis.